Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
Hepatology2013Vol. 58(3), pp. 902–911
Citations Over TimeTop 1% of 2013 papers
Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert A. Fridell, Timothy Eley, Nannan Zhou, David Gardiner
Abstract
The treatment failure of daclatasvir and asunaprevir in HCV GT1a patients was associated with both NS5A and NS3 resistance variants in prior null responders. NS5A resistance variants persisted while NS3 resistance variants generally decayed, suggesting a higher relative fitness of NS5A variants.
Related Papers
- → Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy(2015)77 cited
- → In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A(2012)51 cited
- → A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes(2014)50 cited
- → Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy(2017)8 cited
- → Treatment efficacy of all-oral combinations of direct-acting antivirals in chronic hepatitis C patients with NS5A-P32 deletion(2017)2 cited